Piperidinetriol derivatives as inhibitors of...

Details Piperidinetriol derivatives as inhibitors of... Piperidinetriol derivatives as inhibitors of...

2011-08-09

2011-08-09

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S219000

Reexamination Certificate

active

07994198

ABSTRACT:
Compounds of formula (I); wherein R represents various substituent groups, are useful as inhibitors of glucosylceramide synthase.

REFERENCES:
patent: 4407809 (1983-10-01), Junge et al.
patent: 4639436 (1987-01-01), Junge et al.
patent: 4639463 (1987-01-01), Rosner et al.
patent: 5003072 (1991-03-01), Partis et al.
patent: 5051407 (1991-09-01), Boshagen et al.
patent: 5276120 (1994-01-01), Wong et al.
patent: 5798366 (1998-08-01), Platt et al.
patent: 6046214 (2000-04-01), Kristiansen et al.
patent: 6225325 (2001-05-01), Jacob
patent: 6426198 (2002-07-01), Carstea et al.
patent: 6495570 (2002-12-01), Jacob et al.
patent: 6683076 (2004-01-01), Walkley et al.
patent: 7256005 (2007-08-01), Zitzmann et al.
patent: 2001/0044453 (2001-11-01), Jacob et al.
patent: 2004/0019082 (2004-01-01), van der Spoel et al.
patent: 2006/0058349 (2006-03-01), Hussein et al.
patent: 2006/0074107 (2006-04-01), Butters et al.
patent: 2006/0111400 (2006-05-01), Hussein et al.
patent: 2007/0112028 (2007-05-01), Orchard et al.
patent: 2007/0259918 (2007-11-01), Orchard
patent: 2008/0234324 (2008-09-01), Scopes et al.
patent: 3024901 (1982-01-01), None
patent: 0491041 (1992-06-01), None
patent: 0 536 402 (1993-04-01), None
patent: 0536402 (1993-04-01), None
patent: 0 698 012 (1997-01-01), None
patent: H02-306962 (1990-12-01), None
patent: WO 92/00277 (1992-01-01), None
patent: WO 94/26714 (1994-11-01), None
patent: WO 98/02161 (1998-01-01), None
patent: WO 98/30219 (1998-07-01), None
patent: WO 99/24401 (1999-05-01), None
patent: WO 00/33843 (2000-06-01), None
patent: WO 00/56334 (2000-09-01), None
patent: WO 00/62780 (2000-10-01), None
patent: WO 01/10429 (2001-02-01), None
patent: WO 02/055498 (2002-07-01), None
patent: WO 2004/007453 (2004-01-01), None
patent: WO 2004/007454 (2004-01-01), None
patent: WO 2004/111001 (2004-12-01), None
patent: WO 2004/111002 (2004-12-01), None
patent: WO 2005/068426 (2005-07-01), None
Boeshagen et al. “use of 2-hydroxymethyl . . . ” CA 113:126581(1990).
Ezure et al. “Preparation of 1-deoxy . . . ” CA 116:236093 (1992).
Broek et al. “Chemical modification . . . ” CA 119:96007 (1993).
Berg et al. “Herbicidal composition . . . ” CA 96:117597(1982).
Kurihara et al. “Preparation of N-substi . . . ” CA 114:185939 (1991).
Kato et al. “Biological properties of . . . ” J. Med. Chem. 48 p. 2036-44 (2005).
Prodrug definition MedicineNet.com (from internet) p. 1 (2009).
Abe, A., et al., “Reduction of globotriaosylceramide in fabry disease mice by substrate deprivation,”J. Clin. Invest., 2000, 105(11), 1563-1571.
Alessandri, G., et al., “Angiogenic and angiostatic microenvironment in tumors,”Acta. Oncol., 1997, 36, 383-387.
Alter, M., “GM1 ganglioside for acute ischemic stroke—trial design issues,”Ann. NY Acad. Sci., 1998, 845, 391-401.
Bramer, S.L., et al., “Biologic activity of 5′-deoxy-5-fluorouridine by rectal administration,”Pharmaceutical Res., 1989, 6(4), 318-322.
Chatterjee, S., et al., “Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease,”J. of Lipid. Res., 1996, 37, 1334-1344.
Chen, C.-S., et al., “Abnormal transport along the lysosomal pathway in mucolipidosis, type IV disease,”Proc. Natl. Acad. Sci. USA, 1998, 95, 6373-6378.
Choo-Smith, L.-P., et al., “Acceleration of amyloidfibril formation by specific binding of Aβ-(1-40) peptide to ganglioside-containing membrane vesicles,”J. of Biol. Chem., 1997, 272(37), 22987-22990.
Cox, T., et al., “Novel oral treatment of Gaucher's disease withN-butyldeoxynojirimycin (OBT 918) to decrease substrate biosynthesis,”The Lancet, 2000, 355, 1481-1485.
De Man, P., et al., “Bacterial adherence as a virulence factor in urinary tract infection,”APMIS, 1990, 98, 1053-1060.
Fowler, P.A., et al., “Synthesis and activity towards yeast α-glucosidase of 1,5-dideoxy-1,5-imino-L-iditol (1-deoxy-L-idonojirimycin),”Carbohydr. Res., 1993, 246, 377-381.
Geisler, F.H., “Clinical trials of pharmacotherapy for spinal cord injury,”Ann. NY Acad. Sci., 1998, 845, 374-381.
Goodman, L.A., et al., “Ectopic dendrites occur only on cortical pyramidal cells containing elevated GM2 ganglioside in α-mannosidosis,”Proc. Natl. Acad. Sci. USA, 1991, 88, 11330-11334.
Handa, K., et al., “Analysis of glycolipid-dependent cell adhesion based on carbohydrate-carbohydrate interaction,”Methods in Enzymol., 2000, 312, 447-458.
Hansson, G.C., et al., “A novel approach to the study of glycolipid receptors for viruses,”FEBS Lett., 1984, 170(1),15-18.
Jaranowska, A., et al., “Platelet-activating factor production by human fetal microglia,”Mol.&Chem. Neuropathol., 1995, 24, 95-106.
Jimenez-Lucho, V., et al., “Cryptococcus neoformans, Candida albicans, and other fungi bind specifically to the glycosphingolipid lactosylceramide (Ga1β1-4Glcβ1-1Cer), a possible adhesion receptor for yeasts,”Infect.&Immun., 1990, 58(7), 2085-2090.
Jeyakumar, M., et al., “Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated withN-butyldeoxynojirimycin,”Proc. Natl. Acad. Sci. USA, 1999, 96, 6388-6393.
Lavie, Y., et al., “Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporine A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells,”J. of Biol. Chem., 1997, 272(3), 1682-1687.
Li, R., et al., “Cellular gangliosides promote growth factor-induced proliferation of fibroblasts,”J. of Biol. Chem., 2000, 275(44), 34213-34223.
Lingwood, C.A., et al., “Analysis of interactions between glycosphingolipids and microbial toxins,”Methods in Enzymol., 2000, 312, 459-473.
Liu, Y.-Y., et al., “Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance,”J. Biol. Chem., 2000, 275(10), 7138-7143.
Lucci, A., et al., “Glucosylceramide: a marker for multiple-drug resistant cancers,”Anticancer Res., 1998, 18, 475-480.
McKallip, R., et al., “Tumor gangliosides inhibit the tumor-specific immune response,”J. Immunol., 1999, 163, 3718-3726.
Memon, R.A., et al., “Regulation of glycosphingolipid metabolism in liver during the acute phase response,”J. Of Biol. Chem., 1999, 274(28), 19707-19713.
Memon, R.A., et al., “Regulation of sphingolipid and glycosphingolipid metabolism in extrahepatic tissues by endotoxin,”J. of Lipid. Res., 2001, 42, 452-459.
Merrer, Y.L., et al., “Synthesis of azasugars as potent inhibitors of glycosidases,” 1997, 5(3), 519-533.
Nicholson, K.M., et al., “Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase,”Br. J. Cancer, 1999, 81(3), 423-430.
Overkleeft, H.S., et al., “Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase,”J. of Biol. Chem., 1998, 273(41), 26522-26527.
Platt, F.M., et al., “N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affectN-linked oligosaccharide processing,”J. Biol. Chem., 1994, 269(43), 27108-27114.
Platt, F.M., et al, “Prevention of lysosomal storage in tay-sachs mice treated withN-butyldeoxynojirimycin,”Science, 1997, 276, 428-431.
Poitout, L., et al., “Synthesis of azasugars. Part 1—Simerization of polyhydroxylated piperidines,”Tetrahedron Letts., 1996, 3 7(10), 1609-1612.
Prokazova, N. V., et al., “Gangliosides and atherosclerosis,”Lipids, 1994, 29, 1-5.
Rao, V.S., et al., “Regioselective eliminations in reactions of carbohydrate derivatives with superoxide, or with borohydride in 2-propanol,”Can. J. Chem., 1981, 59(2), 333-338.
Ryan, J.L., et al., &

Affiliated with

Also associated with

Rating

Piperidinetriol derivatives as inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Piperidinetriol derivatives as inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidinetriol derivatives as inhibitors of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2671995